AI tool aims to revolutionize lung cancer screening
NCT ID NCT07408531
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether an artificial intelligence tool called Sybil can improve lung cancer screening by better predicting who is at risk. Researchers will analyze low-dose CT scans from 2,500 people aged 50-80 and compare AI results with current screening guidelines. The goal is to see if AI can catch more cancers earlier, especially in people not covered by standard recommendations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sybil Artificial Intelligence (AI) screening tool
What this could lead to
If successful, this could lead to more accurate and inclusive lung cancer screening, catching more cases early in people who currently fall outside standard guidelines.
What could go wrong
This is an early-stage observational study, not a treatment trial. The AI tool may not perform better than current methods, and results may not apply to all populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER SCREENING are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UI Health 55th and Pulaski Health Collaborative
RECRUITINGChicago, Illinois, 60629, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Illinois Cancer Center
RECRUITINGChicago, Illinois, 60612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••